Cancer Gene Therapy Market by Product Type (Viral Gene Therapy, Non-Viral Gene Therapy), by Application (Immunotherapy, Targeted Therapy, Genetic Modification, Oncolytic Virotherapy), by End-User Industry (Hospitals, Cancer Research Institutes, Biopharmaceutical Companies), by Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Leukemia, Lymphoma); Global Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Cancer Gene Therapy Market was valued at USD 5.4 billion in 2023 and will surpass USD 16.1 billion by 2030; growing at a CAGR of 17.0% during 2024 - 2030. The cancer gene therapy market is a rapidly growing sector within the broader field of cancer treatment, leveraging the power of genetics to alter or repair cells to fight cancer. This market involves various advanced techniques, including viral and non-viral gene therapies, as well as promising approaches like CAR-T therapy and oncolytic virotherapy. The market’s expansion is driven by increasing cancer prevalence, the demand for personalized medicine, and significant advancements in biotechnology and genetic engineering. As these therapies continue to progress through clinical trials and receive regulatory approval, they are poised to play a critical role in revolutionizing cancer treatment. Viral Gene Therapy is Largest Owing to Its Proven Effectiveness Viral gene therapy remains the largest subsegment in the cancer gene therapy market. This approach involves using engineered viruses to deliver therapeutic genes into cancer cells, where they can modify the genetic makeup of the cells and disrupt their growth. Viral vectors are particularly effective in targeting specific cancer cells and have been at the forefront of clinical trials for the treatment of various cancers, including leukemia, lymphoma, and solid tumors. The high efficacy of viral gene therapies in treating hematological cancers has driven their widespread adoption, positioning them as the dominant form of gene therapy in the market. Viral gene therapy’s success lies in its ability to deliver genetic material directly to targeted cells, increasing precision in treatment and reducing the risk of harm to surrounding healthy tissues. As a result, therapies like CAR-T cell therapy, which are derived from viral vectors, are becoming increasingly recognized for their transformative potential in oncology. With continued advancements in viral vector technology and increasing clinical approvals, viral gene therapy is expected to remain a major player in the market for the foreseeable future. Immunotherapy Segment is Fastest Growing Owing to Personalized Treatment Immunotherapy has emerged as the fastest growing application in the cancer gene therapy market. This approach uses the body's immune system to target and destroy cancer cells, often through the genetic modification of immune cells to enhance their ability to recognize and attack tumors. Immunotherapies such as CAR-T and T-cell receptor therapies are being developed for various cancer types, including breast, lung, and colorectal cancers. These therapies are gaining attention because they offer a personalized treatment approach that adapts to the genetic profile of individual patients, thus improving treatment efficacy. The surge in immunotherapy's popularity is driven by its remarkable success in treating cancers that were previously considered difficult to treat, including certain blood cancers and solid tumors. With continued breakthroughs and the increasing focus on immune system modulation, immunotherapy is expected to experience the highest growth in the market, offering a new frontier in personalized cancer treatments. As more immunotherapies gain regulatory approval, this segment will likely dominate the cancer gene therapy landscape in the coming years. Biopharmaceutical Companies Lead End-User Industry in Cancer Gene Therapy Biopharmaceutical companies are the leading end-user industry in the cancer gene therapy market. These companies are responsible for the research, development, and commercialization of novel gene therapies for cancer. With the increasing emphasis on precision medicine and personalized therapies, biopharmaceutical firms are investing heavily in gene therapy innovations, collaborating with academic institutions and other organizations to advance clinical trials and bring therapies to market. The involvement of established biopharmaceutical companies ensures that cancer gene therapies receive the necessary research funding, expertise, and regulatory support to reach the market. Biopharmaceutical companies are also instrumental in expanding access to cutting-edge cancer treatments. Through partnerships with hospitals, research institutes, and other healthcare providers, they ensure that effective gene therapies can be delivered to patients worldwide. As gene therapies continue to demonstrate their potential in clinical trials, biopharmaceutical companies will remain at the forefront of developing and commercializing these revolutionary treatments. Lung Cancer Remains the Most Treated Cancer Type in Gene Therapy Lung cancer is the most commonly treated cancer type within the cancer gene therapy market. As one of the most prevalent and deadliest forms of cancer globally, lung cancer has become a major focus for gene therapy research. The genetic complexity of lung cancer makes it an ideal candidate for targeted therapies, including gene therapy approaches that modify the patient’s cells or use oncolytic viruses to target the cancer directly. Significant research is being conducted to develop viral and non-viral gene therapies specifically for lung cancer, with encouraging results in clinical trials. The high incidence and mortality rates associated with lung cancer, particularly non-small cell lung cancer (NSCLC), have driven intense research into new therapeutic options. Gene therapies that utilize advanced viral vectors, such as adenoviruses and lentiviruses, are being explored to deliver targeted therapies more effectively to lung cancer cells. As clinical data continues to support the effectiveness of these therapies, lung cancer will remain a key area of focus in the cancer gene therapy market. North America is the Largest Region in the Cancer Gene Therapy Market North America leads the global cancer gene therapy market in terms of revenue and market share. The region's dominance is due to the robust healthcare infrastructure, significant investments in biotechnology research, and the presence of major biopharmaceutical companies engaged in developing gene therapies. The U.S., in particular, has been at the forefront of gene therapy innovations, with numerous clinical trials and regulatory approvals for gene-based cancer treatments. In addition, North America benefits from favorable regulatory environments, which facilitate the rapid approval of gene therapies. The region's large healthcare expenditure and strong focus on cancer research and development have created a conducive environment for gene therapy advancements. As new therapies are approved and enter the market, North America's position as the leading region is expected to remain unchallenged, driving significant growth and expansion in the cancer gene therapy sector. Leading Companies and Competitive Landscape Leading companies in the cancer gene therapy market include Novartis AG, Gilead Sciences, Bristol-Myers Squibb, Amgen Inc., Kite Pharma (a Gilead Company), and Bluebird Bio, among others. These companies are heavily involved in the development of gene-based cancer treatments, often through strategic partnerships, acquisitions, and clinical trials. With the increasing focus on personalized medicine, these companies are leveraging cutting-edge technologies to enhance the efficacy and safety of gene therapies. The competitive landscape of the cancer gene therapy market is characterized by intense research and development efforts, as well as collaborations between biopharmaceutical companies, research institutions, and healthcare providers. The market is witnessing significant mergers and acquisitions as companies seek to expand their portfolios and gain access to innovative therapies. Additionally, regulatory bodies such as the FDA and EMA play a crucial role in shaping the competitive dynamics by approving or rejecting new therapies based on safety and efficacy data. As the market grows, competition will intensify, leading to continuous innovation and a wide array of treatment options for cancer patients. Recent Developments: • Novartis AG received FDA approval for its Kymriah CAR-T therapy for additional cancer types, expanding its use in treating various hematologic cancers. • Bluebird Bio announced positive results in their clinical trials for a gene therapy treatment for sickle cell disease and solid tumors, with promising data for cancer treatment. • Gilead Sciences completed the acquisition of Kite Pharma, enhancing its portfolio in the cancer gene therapy market, particularly for CAR-T cell therapies. • Amgen Inc. launched a new oncolytic virus-based gene therapy treatment aimed at targeting solid tumors, marking a significant advancement in the field of oncolytic virotherapy. • Sangamo Therapeutics entered into a strategic partnership with Pfizer to co-develop gene therapy solutions targeting hematologic cancers, leveraging gene editing technologies to treat genetic mutations. List of Leading Companies: • Novartis AG • Gilead Sciences • Merck & Co., Inc. • Bayer AG • Janssen Pharmaceuticals (Johnson & Johnson) • Bristol-Myers Squibb • Bluebird Bio • Amgen Inc. • Sangamo Therapeutics • Pfizer Inc. • Sarepta Therapeutics • Celyad Oncology • Kite Pharma (Gilead Sciences) • Adaptimmune Therapeutics • Genprex, Inc. Report Scope: Report Features Description Market Size (2023) USD 5.4 Billion Forecasted Value (2030) USD 16.1 Billion CAGR (2024 – 2030) 17.0% Base Year for Estimation 2023 Historic Year 2022 Forecast Period 2024 – 2030 Report Coverage Market Forecast, Market Dynamics, Competitive Landscape, Recent Developments Segments Covered Cancer Gene Therapy Market by Product Type (Viral Gene Therapy, Non-Viral Gene Therapy), by Application (Immunotherapy, Targeted Therapy, Genetic Modification, Oncolytic Virotherapy), by End-User Industry (Hospitals, Cancer Research Institutes, Biopharmaceutical Companies), by Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Leukemia, Lymphoma) Regional Analysis North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, South Korea, Australia, India, and Rest of Asia-Pacific), Latin America (Brazil, Argentina, and Rest of Latin America), Middle East & Africa (Saudi Arabia, UAE, Rest of Middle East & Africa) Major Companies Novartis AG, Gilead Sciences, Merck & Co., Inc., Bayer AG, Janssen Pharmaceuticals (Johnson & Johnson), Bristol-Myers Squibb, Bluebird Bio, Amgen Inc., Sangamo Therapeutics, Pfizer Inc., Sarepta Therapeutics, Celyad Oncology, Kite Pharma (Gilead Sciences), Adaptimmune Therapeutics, Genprex, Inc. Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements